Intracellular delivery of polymeric nanocarriers: A matter of size, shape, charge, elasticity and surface composition

Therapeutic Delivery

Volumn 4, Issue 6, 2013, Pages 705-723

  Agarwal, Rachit ^a   Roy, Krishnendu ^a  

^a The University of Texas at Austin   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLATHRIN; DRUG CARRIER; MACROGOL; NANOCARRIER; POLYMER; POLYSACCHARIDE; QUANTUM DOT;

CAVEOLA; CELL MEMBRANE TRANSPORT; CELL ORGANELLE; CHEMICAL COMPOSITION; COMPLEMENT SYSTEM; CYTOSOL; DIFFUSION; DRUG COATING; DRUG DELIVERY SYSTEM; ELASTICITY; ENDOCYTOSIS; HUMAN; INTERNALIZATION; LIVER; LYSOSOME; MAMMAL CELL; NONHUMAN; OPSONIZATION; PARTICLE SIZE; PHAGOCYTOSIS; PINOCYTOSIS; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; REVIEW; SURFACE CHARGE;

EID: 84878727003     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.13.37     Document Type: Review

References (162)

1. Korfee S, Gauler T, Hepp R, Pottgen C, Eberhardt W. New targeted treatments in lung cancer - overview of clinical trials. Lung Cancer 45(Suppl. 2), S199-S208 (2004).
2. Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7(9), 771-782 (2008).
3. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 5(3), 161-171 (2005).
4. Hamidi M, Azadi A, Rafiei P. Hydrogel nanoparticles in drug delivery. Adv. Drug Deliv. Rev. 60(15), 1638-1649 (2008).
5. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 55(3), 329-347 (2003).
6. Peppas NA. Intelligent therapeutics: biomimetic systems and nanotechnology in drug delivery. Adv. Drug Deliv. Rev. 56(11), 1529-1531 (2004).
7. Schafer V, Von Briesen H, Andreesen R et al. Phagocytosis of nanoparticles by human immunodeficiency virus (HIV)-infected macrophages: a possibility for antiviral drug targeting. Pharm. Res. 9(4), 541-546 (1992).
8. Nel A, Xia T, Madler L, Li N. Toxic potential of materials at the nanolevel. Science 311(5761), 622-627 (2006).
9. Teeguarden JG, Hinderliter PM, Orr G, Thrall BD, Pounds JG. Particokinetics in vitro: dosimetry considerations for in vitro nanoparticle toxicity assessments.Toxicol. Sci. 95(2), 300-312 (2007).
10. Lison D, Thomassen Lc, Rabolli V et al. Nominal and effective dosimetry of silica nanoparticles in cytotoxicity assays. Toxicol. Sci. 104(1), 155-162 (2008).
11. Ballou B, Lagerholm BC, Ernst LA, Bruchez MP, Waggoner AS. Noninvasive imaging of quantum dots in mice. Bioconjug. Chem. 15(1), 79-86 (2004).
12. Liao H, Nehl CL, Hafner JH. Biomedical applications of plasmon resonant metal nanoparticles. Nanomedicine (Lond.) 1(2), 201-208 (2006).
13. Dykman L, Khlebtsov N. Gold nanoparticles in biomedical applications: recent advances and perspectives. Chem. Soc. Rev. 41(6), 2256-2282 (2012).
14. Bhowmick T, Berk E, Cui X, Muzykantov VR, Muro S. Effect of flow on endothelial endocytosis of nanocarriers targeted to ICAM-1. J. Control. Release 157(3), 485-492 (2012).
15. Han J, Zern BJ, Shuvaev VV, Davies PF, Muro S, Muzykantov V. Acute and chronic shear stress differently regulate endothelial internalization of nanocarriers targeted to platelet-endothelial cell adhesion molecule-1. ACS Nano 6(10), 8824-8836 (2012).
16. Doherty GJ, Mcmahon HT. Mechanisms of endocytosis. Annu. Rev Biochem. 78, 857-902 (2009).
17. Parton RG, Simons K. The multiple faces of caveolae. Nat. Rev. Mol. Cell. Biol. 8(3), 185-194 (2007).
18. Ivanov AI. Pharmacological inhibition of endocytic pathways: is it specific enough to be useful? Methods Mol. Biol. 440, 15-33 (2008).
19. Hoffmann PR, Decathelineau AM, Ogden CA et al. Phosphatidylserine (PS) induces PS receptor-mediated macropinocytosis and promotes clearance of apoptotic cells. J. Cell Biol. 155(4), 649-659 (2001).
20. Henson PM, Bratton DL, Fadok VA. Apoptotic cell removal. Curr. Biol. 11(19), R795-R805 (2001).
21. Chen Y, Wang S, Lu X, Zhang H, Fu Y, Luo Y. Cholesterol sequestration by nystatin enhances the uptake and activity of endostatin in endothelium via regulating distinct endocytic pathways. Blood 117(23), 6392-6403 (2011).
22. Huth US, Schubert R, Peschka-Suss R. Investigating the uptake and intracellular fate of pH-sensitive liposomes by flow cytometry and spectral bio-imaging. J. Control. Release 110(3), 490-504 (2006).
23. Georgieva Jv, Kalicharan D, Couraud Po et al. Surface characteristics of nanoparticles determine their intracellular fate in and processing by human blood-brain barrier endothelial cells in vitro. Mol. Ther. 19(2), 318-325 (2011).
24. Bhattacharya S, Roxbury D, Gong X, Mukhopadhyay D, Jagota A. DNA conjugated SWCNTs enter endothelial cells via Rac1 mediated macropinocytosis. Nano Lett. 12(4), 1826-1830 (2012).
25. Mundy DI, Li WP, Luby-Phelps K, Anderson RG. Caveolin targeting to late endosome/lysosomal membranes is induced by perturbations of lysosomal pH and cholesterol content. Mol. Biol. Cell 23(5), 864-880 (2012).
26. Mettlen M, Loerke D, Yarar D, Danuser G, Schmid SL. Cargo- and adaptor-specific mechanisms regulate clathrin-mediated endocytosis. J. Cell Biol. 188(6), 919-933 (2010).
27. Sandgren KJ, Wilkinson J, Miranda-Saksena M et al. A differential role for macropinocytosis in mediating entry of the two forms of vaccinia virus into dendritic cells. PLoS Pathog. 6(4), e1000866 (2010).
28. Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature 422(6927), 37-44 (2003).
29. Mayor S, Pagano RE. Pathways of clathrin-independent endocytosis. Nat. Rev. Mol. Cell Biol. 8(8), 603-612 (2007).
30. Edidin M. Shrinking patches and slippery rafts: scales of domains in the plasma membrane. Trends Cell Biol. 11(12), 492-496 (2001).
31. Sahay G, Alakhova DY, Kabanov AV. Endocytosis of nanomedicines. J. Control. Release 145(3), 182-195 (2010).
32. Hewlett LJ, Prescott AR, Watts C. The coated pit and macropinocytic pathways serve distinct endosome populations. J. Cell Biol. 124(5), 689-703 (1994).
33. Korn ED, Weisman RA. Phagocytosis of latex beads by Acanthamoeba. II. Electron microscopic study of the initial events. J. Cell Biol. 34(1), 219-227 (1967).
34. Agarwal R, Singh V, Jurney P, Shi L, Sreenivasan SV, Roy K. Scalable imprinting of shape-specific polymeric nanocarriers using a release layer of switchable water solubility. ACS Nano 6(3), 2524-2531 (2012).
35. Glangchai LC, Caldorera-Moore M, Shi L, Roy K. Nanoimprint lithography based fabrication of shape-specific, enzymatically-triggered smart nanoparticles. J. Control. Release 125(3), 263-272 (2008).
36. Rolland JP, Maynor BW, Euliss LE, Exner AE, Denison GM, Desimone JM. Direct fabrication and harvesting of monodisperse, shape-specific nanobiomaterials. J. Am. Chem. Soc. 127(28), 10096-10100 (2005).
37. Tasciotti E, Liu X, Bhavane R et al. Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat. Nanotechnol. 3(3), 151-157 (2008).
38. Canelas DA, Herlihy KP, Desimone JM. Top-down particle fabrication: control of size and shape for diagnostic imaging and drug delivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 1(4), 391-404 (2009).
39. Acharya G, Shin CS, Mcdermott M et al. The hydrogel template method for fabrication of homogeneous nano/microparticles. J. Control. Release 141(3), 314-319 (2010).
40. Osaki F, Kanamori T, Sando S, Sera T, Aoyama Y. A quantum dot conjugated sugar ball and its cellular uptake. On the size effects of endocytosis in the subviral region. J. Am. Chem. Soc. 126(21), 6520-6521 (2004).
41. Chithrani BD, Ghazani AA, Chan WC. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 6(4), 662-668 (2006).
42. Lu F, Wu Sh, Hung Y, Mou CY. Size effect on cell uptake in well-suspended, uniform mesoporous silica nanoparticles. Small 5(12), 1408-1413 (2009).
43. He C, Hu Y, Yin L, Tang C, Yin C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 31(13), 3657-3666 (2010).
44. Rudolph C, Plank C, Lausier J, Schillinger U, Muller RH, Rosenecker J. Oligomers of the arginine-rich motif of the HIV-1 TAT protein are capable of transferring plasmid DNA into cells. J. Biol. Chem. 278(13), 11411-11418 (2003).
45. Oh E, Delehanty JB, Sapsford KE et al. Cellular uptake and fate of PEGylated gold nanoparticles is dependent on both cell-penetration peptides and particle size. ACS Nano 5(8), 6434-6448 (2011).
46. Rejman J, Oberle V, Zuhorn IS, Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem. J. 377(Pt 1), 159-169 (2004).
47. Rejman J, Conese M, Hoekstra D. Gene transfer by means of lipo- and polyplexes: role of clathrin and caveolae-mediated endocytosis. J. Liposome Res. 16(3), 237-247 (2006).
48. Rejman J, Bragonzi A, Conese M. Role of clathrin- and caveolae-mediated endocytosis in gene transfer mediated by lipo- and polyplexes. Mol. Ther. 12(3), 468-474 (2005).
49. Choi HS, Liu W, Misra P et al. Renal clearance of quantum dots. Nat. Biotechnol. 25(10), 1165-1170 (2007).
50. Ilium L, Davis SS, Wilson CG, Thomas NW, Frier M, Hardy JG. Blood clearance and organ deposition of intravenously administered colloidal particles. The effects of particle size, nature and shape. Int. J. Pharm. 12(2-3), 135-146 (1982).
51. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 7(11), 653-664 (2010).
52. Hobbs SK, Monsky WL, Yuan F et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl Acad. Sci. USA 95(8), 4607-4612 (1998).
53. Yuan F, Dellian M, Fukumura D et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 55(17), 3752-3756 (1995).
54. Unezaki S, Maruyama K, Hosoda JI et al. Direct measurement of the extravasation of polyethyleneglycol-coated liposomes into solid tumor tissue by in vivo fluorescence microscopy. Int. J. Pharm. 144(1), 11-17 (1996).
55. Longmire M, Choyke Pl, Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (Lond.) 3(5), 703-717 (2008).
56. Shuvaev VV, Tliba S, Pick J et al. Modulation of endothelial targeting by size of antibody-antioxidant enzyme conjugates. J. Control. Release 149(3), 236-241 (2011).
57. Moghimi SM. Mechanisms of splenic clearance of blood cells and particles: towards development of new splenotropic agents. Adv. Drug Deliv. Rev. 17(1), 103-115 (1995).
58. Perrault SD, Walkey C, Jennings T, Fischer HC, Chan WC. Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett. 9(5), 1909-1915 (2009).
59. Caldorera-Moore M, Guimard N, Shi L, Roy K. Designer nanoparticles: incorporating size, shape and triggered release into nanoscale drug carriers. Expert Opin. Drug Deliv. 7(4), 479-495 (2010).
60. Tao L, Hu W, Liu Y, Huang G, Sumer BD, Gao J. Shape-specific polymeric nanomedicine: emerging opportunities and challenges. Exp. Biol. Med. 236(1), 20-29.
61. Champion JA, Katare YK, Mitragotri S. Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers. J. Control. Release 121(1-2), 3-9 (2007).
62. Simone EA, Dziubla TD, Muzykantov VR. Polymeric carriers: role of geometry in drug delivery. Expert Opin. Drug Deliv. 5(12), 1283-1300 (2008).
63. Liu Y, Tan J, Thomas A, Ou-Yang D, Muzykantov VR. The shape of things to come: importance of design in nanotechnology for drug delivery. Ther. Deliv. 3(2), 181-194 (2012).
64. Toy R, Hayden E, Shoup C, Baskaran H, Karathanasis E. The effects of particle size, density and shape on margination of nanoparticles in microcirculation. Nanotechnology 22(11), 115101 (2011).
65. Peiris PM, Bauer L, Toy R et al. Enhanced delivery of chemotherapy to tumors using a multicomponent nanochain with radio-frequency-tunable drug release. ACS Nano 6(5), 4157-4168 (2012).
66. Huang X, Teng X, Chen D, Tang F, He J. The effect of the shape of mesoporous silica nanoparticles on cellular uptake and cell function. Biomaterials 31(3), 438-448 (2010).
67. Gratton SE, Ropp PA, Pohlhaus PD et al. The effect of particle design on cellular internalization pathways. Proc. Natl Acad. Sci. USA 105(33), 11613-11618 (2008).
68. Champion JA, Mitragotri S. Role of target geometry in phagocytosis. Proc. Natl Acad. Sci. USA 103(13), 4930-4934 (2006).
69. Barua S, Yoo JW, Kolhar P, Wakankar A, Gokarn YR, Mitragotri S. Particle shape enhances specificity of antibody-displaying nanoparticles. Proc. Natl Acad. Sci. USA 110(9), 3270-3275 (2013).
70. Lee Kj, Yoon J, Rahmani S et al. Spontaneous shape reconfigurations in multicompartmental microcylinders. Proc. Natl Acad. Sci. USA 109(40), 16057-16062 (2012).
71. Yoo JW, Mitragotri S. Polymer particles that switch shape in response to a stimulus. Proc. Natl Acad. Sci. USA 107(25), 11205-11210 (2010).
72. Yoo JW, Doshi N, Mitragotri S. Adaptive micro and nanoparticles: temporal control over carrier properties to facilitate drug delivery. Adv. Drug Deliv. Rev. 63(14-15), 1247-1256 (2011).
73. Yoo JW, Irvine DJ, Discher DE, Mitragotri S. Bio-inspired, bioengineered and biomimetic drug delivery carriers. Nat. Rev. Drug Discov. 10(7), 521-535 (2011).
74. Decuzzi P, Lee S, Bhushan B, Ferrari M. A theoretical model for the margination of particles within blood vessels. Ann. Biomed. Eng. 33(2), 179-190 (2005).
75. Shah S, Liu Y, Hu W, Gao J. Modeling particle shape-dependent dynamics in nanomedicine. J. Nanosci. Nanotechnol. 11(2), 919-928 (2011).
76. van De Ven AL, Kim P, Haley O et al. Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution. J. Control. Release 158(1), 148-155 (2012).
77. Geng Y, Dalhaimer P, Cai S et al. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat. Nanotechnol. 2(4), 249-255 (2007).
78. Merkel TJ, Jones SW, Herlihy KP et al. Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles. Proc. Natl Acad. Sci. USA 108(2), 586-591 (2011).
79. Doshi N, Zahr AS, Bhaskar S, Lahann J, Mitragotri S. Red blood cell-mimicking synthetic biomaterial particles. Proc. Natl Acad. Sci. USA 106(51), 21495-21499 (2009).
80. Chauhan VP, Popovic Z, Chen O et al. Fluorescent nanorods and nanospheres for real-time in vivo probing of nanoparticle shape-dependent tumor penetration. Angew. Chem. Int. Ed. Engl. 50(48), 11417-11420 (2011).
81. Smith BR, Kempen P, Bouley D et al. Shape matters: intravital microscopy reveals surprising geometrical dependence for nanoparticles in tumor models of extravasation. Nano Lett. 12(7), 3369-3377 (2012).
82. Yang K, Ma YQ. Computer simulation of the translocation of nanoparticles with different shapes across a lipid bilayer. Nat. Nanotechnol. 5(8), 579-583 (2010).
83. Jiang X, Qu W, Pan D et al. Plasmid-templated shape control of condensed DNA-block copolymer nanoparticles. Adv. Mater. 25(2), 227-232 (2012).
84. Belting M. Heparan sulfate proteoglycan as a plasma membrane carrier. Trends Biochem. Sci. 28(3), 145-151 (2003).
85. Albanese A, Tang PS, Chan WC. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu. Rev. Biomed. Eng. 14, 1-16 (2012).
86. Thorek DL, Tsourkas A. Size, charge and concentration dependent uptake of iron oxide particles by non-phagocytic cells. Biomaterials 29(26), 3583-3590 (2008).
87. Arvizo RR, Miranda OR, Thompson MA et al. Effect of nanoparticle surface charge at the plasma membrane and beyond. Nano. Lett. 10(7), 2543-2548 (2010).
88. Wang B, Zhang L, Bae SC, Granick S. Nanoparticle-induced surface reconstruction of phospholipid membranes. Proc. Natl Acad. Sci. USA 105(47), 18171-18175 (2008).
89. Perumal OP, Inapagolla R, Kannan S, Kannan RM. The effect of surface functionality on cellular trafficking of dendrimers. Biomaterials 29(24-25), 3469-3476 (2008).
90. Harush-Frenkel O, Rozentur E, Benita S, Altschuler Y. Surface charge of nanoparticles determines their endocytic and transcytotic pathway in polarized MDCK cells. Biomacromolecules 9(2), 435-443 (2008).
91. Callahan J, Kopecek J. Semitelechelic HPMA copolymers functionalized with triphenylphosphonium as drug carriers for membrane transduction and mitochondrial localization. Biomacromolecules 7(8), 2347-2356 (2006).
92. Harush-Frenkel O, Debotton N, Benita S, Altschuler Y. Targeting of nanoparticles to the clathrin-mediated endocytic pathway. Biochem. Biophys. Res. Commun. 353(1), 26-32 (2007).
93. Sahay G, Kim JO, Kabanov AV, Bronich TK. The exploitation of differential endocytic pathways in normal and tumor cells in the selective targeting of nanoparticulate chemotherapeutic agents. Biomaterials 31(5), 923-933 (2010).
94. Zhang LW, Monteiro-Riviere NA. Mechanisms of quantum dot nanoparticle cellular uptake. Toxicol. Sci. 110(1), 138-155 (2009).
95. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2(12), 751-760 (2007).
96. Campbell RB, Fukumura D, Brown EB et al. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res. 62(23), 6831-6836 (2002).
97. Stylianopoulos T, Soteriou K, Fukumura D, Jain RK. Cationic nanoparticles have superior transvascular flux into solid tumors: insights from a mathematical model. Ann. Biomed. Eng. 41(1), 68-77 (2013).
98. Cedervall T, Lynch I, Lindman S et al. Understanding the nanoparticle-protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles. Proc. Natl Acad. Sci. USA 104(7), 2050-2055 (2007).
99. Lynch I, Dawson KA. Protein-nanoparticle interactions. Nano Today 3(1-2), 40-47 (2008).
100. Lynch I, Salvati A, Dawson KA. Protein-nanoparticle interactions: what does the cell see? Nat. Nanotechnol. 4(9), 546-547 (2009).
101. Domański DM, Klajnert B, Bryszewska M. Influence of PAMAM dendrimers on human red blood cells. Bioelectrochemistry 63(1-2), 189-191 (2004).
102. Malik N, Wiwattanapatapee R, Klopsch R et al. Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J. Control. Release 65(1-2), 133-148 (2000).
103. Kim B, Han G, Toley BJ, Kim CK, Rotello VM, Forbes NS. Tuning payload delivery in tumour cylindroids using gold nanoparticles. Nat. Nanotechnol. 5(6), 465-472 (2010).
104. Discher DE, Janmey P, Wang YL. Tissue cells feel and respond to the stiffness of their substrate. Science 310(5751), 1139-1143 (2005).
105. Yi X, Shi X, Gao H. Cellular uptake of elastic nanoparticles. Phys. Rev. Lett. 107(9), 098101 (2011).
106. Banquy X, Suarez F, Argaw A et al. Effect of mechanical properties of hydrogel nanoparticles on macrophage cell uptake. Soft Matter 5(20), 3984-3991 (2009).
107. Petros RA, Desimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 9(8), 615-627 (2010).
108. Oldenborg PA, Gresham HD, Chen Y, Izui S, Lindberg FP. Lethal autoimmune hemolytic anemia in CD47-deficient nonobese diabetic (NOD) mice. Blood 99(10), 3500-3504 (2002).
109. Merkel TJ, Chen K, Jones SW et al. The effect of particle size on the biodistribution of low-modulus hydrogel PRINT particles. J. Control. Release 162(1), 37-44 (2012).
110. Li Y, Chen X, Gu N. Computational investigation of interaction between nanoparticles and membranes: hydrophobic/hydrophilic effect. J. Phys. Chem. B 112(51), 16647-16653 (2008).
111. Brandenberger C, Muhlfeld C, Ali Z et al. Quantitative evaluation of cellular uptake and trafficking of plain and polyethylene glycol-coated gold nanoparticles. Small 6(15), 1669-1678 (2010).
112. Lin C, Engbersen JF. Effect of chemical functionalities in poly(amido amine)s for non-viral gene transfection. J. Control. Release 132(3), 267-272 (2008).
113. Jenssen H, Hamill P, Hancock RE. Peptide antimicrobial agents. Clin. Microbiol. Rev. 19(3), 491-511 (2006).
114. Evans CW, Fitzgerald M, Clemons TD et al. Multimodal analysis of PEI-mediated endocytosis of nanoparticles in neural cells. ACS Nano 5(11), 8640-8648 (2011).
115. Brannon-Peppas L, Blanchette JO. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev. 56(11), 1649-1659 (2004).
116. Gaur U, Sahoo SK, De TK, Ghosh PC, Maitra A, Ghosh PK. Biodistribution of fluoresceinated dextran using novel nanoparticles evading reticuloendothelial system. Int. J. Pharm. 202(1-2), 1-10 (2000).
117. Lesniak A, Salvati A, Santos-Martinez MJ, Radomski MW, Dawson KA, Aberg C. Nanoparticle adhesion to the cell membrane and its effect on nanoparticle uptake efficiency. J. Am. Chem. Soc. 135(4), 1438-1444 (2013).
118. Cedervall T, Lynch I, Foy M et al. Detailed identification of plasma proteins adsorbed on copolymer nanoparticles. Angew. Chem. Int. Ed. Engl. 46(30), 5754-5756 (2007).
119. Michaelis K, Hoffmann MM, Dreis S et al. Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. J. Pharmacol. Exp. Ther. 317(3), 1246-1253 (2006).
120. Kim HR, Andrieux K, Gil S et al. Translocation of poly(ethylene glycol-co-hexadecyl)cyanoacrylate nanoparticles into rat brain endothelial cells: role of apolipoproteins in receptor-mediated endocytosis. Biomacromolecules 8(3), 793-799 (2007).
121. Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv. Drug Deliv. Rev. 60(8), 876-885 (2008).
122. Desai N, Trieu V, Yao Z et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin. Cancer Res. 12(4), 1317-1324 (2006).
123. Kim KJ, Malik AB. Protein transport across the lung epithelial barrier. Am. J. Physiol. Lung Cell. Mol. Physiol. 284(2), L247-259 (2003).
124. Klein J. Probing the interactions of proteins and nanoparticles. Proc. Natl Acad. Sci. USA 104(7), 2029-2030 (2007).
125. Yoo JW, Chambers E, Mitragotri S. Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects. Curr. Pharm. Des. 16(21), 2298-2307 (2010).
126. Mosqueira VC, Legrand P, Morgat JL et al. Biodistribution of long-circulating PEG-grafted nanocapsules in mice: effects of PEG chain length and density. Pharm. Res. 18(10), 1411-1419 (2001).
127. Masson C, Garinot M, Mignet N et al. pH-sensitive PEG lipids containing orthoester linkers: new potential tools for nonviral gene delivery. J. Control. Release 99(3), 423-434 (2004).
128. Shin J, Shum P, Thompson DH. Acid-triggered release via dePEGylation of DOPE liposomes containing acid-labile vinyl ether PEG-lipids. J. Control. Release 91(1-2), 187-200 (2003).
129. Hatakeyama H, Akita H, Kogure K et al. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther. 14(1), 68-77 (2007).
130. Zhu L, Kate P, Torchilin VP. Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. ACS Nano 6(4), 3491-3498 (2012).
131. Ishida T, Kiwada H. Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int. J. Pharm. 354(1-2), 56-62 (2008).
132. Ishida T, Wang X, Shimizu T, Nawata K, Kiwada H. PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J. Control. Release 122(3), 349-355 (2007).
133. Wang X, Ishida T, Kiwada H. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J. Control. Release 119(2), 236-244 (2007).
134. Hamad I, Al-Hanbali O, Hunter AC, Rutt KJ, Andresen TL, Moghimi SM. Distinct polymer architecture mediates switching of complement activation pathways at the nanosphere-serum interface: implications for stealth nanoparticle engineering. ACS Nano 4(11), 6629-6638 (2010).
135. Kang YH, Tan LA, Carroll MV, Gentle ME, Sim RB. Target pattern recognition by complement proteins of the classical and alternative pathways. Adv. Exp. Med. Biol. 653, 117-128 (2009).
136. Wallis R, Mitchell DA, Schmid R, Schwaeble WJ, Keeble AH. Paths reunited: initiation of the classical and lectin pathways of complement activation. Immunobiology 215(1), 1-11 (2010).
137. Thomsen T, Schlosser A, Holmskov U, Sorensen GL. Ficolins and FIBCD1: soluble and membrane bound pattern recognition molecules with acetyl group selectivity. Mol. Immunol. 48(4), 369-381 (2011).
138. Schneider MC, Prosser BE, Caesar JJ et al. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature 458(7240), 890-893 (2009).
139. Clark SJ, Higman VA, Mulloy B et al. His- 384 allotypic variant of factor H associated with age-related macular degeneration has different heparin binding properties from the non-disease-associated form. J. Biol. Chem. 281(34), 24713-24720 (2006).
140. Tsai RK, Discher DE. Inhibition of "self " engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J. Cell Biol. 180(5), 989-1003 (2008).
141. Low PS, Henne WA, Doorneweerd DD. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc. Chem. Res. 41(1), 120-129 (2008).
142. Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv. Drug Deliv. Rev. 56(8), 1177-1192 (2004).
143. Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML. The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin. Immunol. 121(2), 144-158 (2006).
144. Daniels TR, Delgado T, Helguera G, Penichet ML. The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin. Immunol. 121(2), 159-176 (2006).
145. Patri AK, Myc A, Beals J, Thomas TP, Bander NH, Baker JR Jr. Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjug. Chem. 15(6), 1174-1181 (2004).
146. Ruoslahti E, Bhatia SN, Sailor MJ. Targeting of drugs and nanoparticles to tumors. J. Cell Biol. 188(6), 759-768 (2010).
147. Jacobson BS, Stolz DB, Schnitzer JE. Identification of endothelial cell-surface proteins as targets for diagnosis and treatment of disease. Nat. Med. 2(4), 482-484 (1996).
148. Davis ME. The first targeted delivery of siRNA in humans via a self-assembling, cyclodextrin polymer-based nanoparticle: from concept to clinic. Mol. Pharm. 6(3), 659-668 (2009).
149. Gu F, Zhang L, Teply BA et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc. Natl Acad. Sci. USA 105(7), 2586-2591 (2008).
150. Shmeeda H, Tzemach D, Mak L, Gabizon A. HER2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage. J. Control. Release 136(2), 155-160 (2009).
151. Stefanick JF, Ashley JD, Kiziltepe T, Bilgicer B. A systematic analysis of peptide linker length and liposomal polyethylene glycol coating on cellular uptake of peptide-targeted liposomes. ACS Nano 7(4), 2935-2947 (2013).
152. Lee H, Fonge H, Hoang B, Reilly RM, Allen C. The effects of particle size and molecular targeting on the intratumoral and subcellular distribution of polymeric nanoparticles. Mol. Pharm. 7(4), 1195-1208 (2010).
153. Hillaireau H, Couvreur P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell. Mol. Life Sci. 66(17), 2873-2896 (2009).
154. Hilgenbrink AR, Low PS. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J. Pharm. Sci. 94(10), 2135-2146 (2005).
155. Dauty E, Remy JS, Zuber G, Behr JP. Intracellular delivery of nanometric DNA particles via the folate receptor. Bioconjug. Chem. 13(4), 831-839 (2002).
156. Jones AR, Shusta EV. Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm. Res. 24(9), 1759-1771 (2007).
157. Huwyler J, Yang J, Pardridge WM. Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat. J. Pharmacol. Exp. Ther. 282(3), 1541-1546 (1997).
158. Tekle C, Deurs B, Sandvig K, Iversen TG. Cellular trafficking of quantum dot-ligand bioconjugates and their induction of changes in normal routing of unconjugated ligands. Nano. Lett. 8(7), 1858-1865 (2008).
159. Verma A, Uzun O, Hu Y et al. Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. Nat. Mater. 7(7), 588-595 (2008).
160. Muro S, Garnacho C, Champion JA et al. Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1- targeted carriers. Mol. Ther. 16(8), 1450-1458 (2008).
161. Shuvaev VV, Ilies MA, Simone E et al. Endothelial targeting of antibody-decorated polymeric filomicelles. ACS Nano 5(9), 6991-6999 (2011).
162. Friedrich J, Seidel C, Ebner R, Kunz- Schughart LA. Spheroid-based drug screen: considerations and practical approach. Nat. Protoc. 4(3), 309-324 (2009).